Overview

Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis

Status:
Recruiting

Trial end date:
2026-06-23

Target enrollment:

Participant gender:

Summary

Prospective, low intervention, open, single-center, non-commercial clinical trial to improve diagnostics in patients with histiocytosis by assessing the molecular profile of the tumor tissues, monitoring its presence in free-circulating DNA, and determining the efficacy of fluorodeoxyglucose (18F-FDG) in PET-CT imaging.

Phase:

Phase 3

Details

Lead Sponsor:

Anna Raciborska

Collaborators:

Łukasiewicz Research Network
Maria Sklodowska-Curie Institute - Oncology Center
Wrocław University of Environmental and Life Sciences

Treatments:

Fluorodeoxyglucose F18